SIGA Technologies, Inc. (SIGA)
NASDAQ: SIGA · Real-Time Price · USD
6.23
-0.02 (-0.24%)
At close: Jan 17, 2025, 4:00 PM
6.16
-0.06 (-1.04%)
Pre-market: Jan 21, 2025, 7:06 AM EST
SIGA Technologies Revenue
SIGA Technologies had revenue of $10.01M in the quarter ending September 30, 2024, with 8.39% growth. This brings the company's revenue in the last twelve months to $173.73M, up 399.31% year-over-year. In the year 2023, SIGA Technologies had annual revenue of $139.92M with 26.31% growth.
Revenue (ttm)
$173.73M
Revenue Growth
+399.31%
P/S Ratio
2.55
Revenue / Employee
$3,860,697
Employees
45
Market Cap
444.49M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 139.92M | 29.14M | 26.31% |
Dec 31, 2022 | 110.78M | -22.89M | -17.13% |
Dec 31, 2021 | 133.67M | 8.71M | 6.97% |
Dec 31, 2020 | 124.96M | 98.22M | 367.28% |
Dec 31, 2019 | 26.74M | -450.31M | -94.39% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
SIGA News
- 18 days ago - TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses - GlobeNewsWire
- 5 weeks ago - Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced - GlobeNewsWire
- 7 weeks ago - SIGA Technologies Vs Emergent BioSolutions: Product Portfolio And Future Outlook - Seeking Alpha
- 2 months ago - SIGA Technologies: Expansion Into mAbs Is Smart, But Eggs Remain In One Basket - Seeking Alpha
- 2 months ago - SIGA Technologies (SIGA) Shares Tumble After Mpox Therapy Fails, Chief Medical Officer Terminated - Hagens Berman - GlobeNewsWire
- 2 months ago - SIGA Technologies, Inc. (SIGA) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - SIGA to Host Business Update Call on November 7 Following Release of Third-Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating SIGA Technologies, Inc. for potential violations of federal securities laws - PRNewsWire